Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an announcement.
Vicore Pharma will showcase a series of new clinical and preclinical data on its ATRAG platform at the 2026 American Thoracic Society International Conference in Orlando, highlighting the breadth of its research in idiopathic pulmonary fibrosis and related pulmonary conditions. The company will present analyses from the completed Phase 2a AIR trial of buloxibutid in IPF, including a comparison of Indian patients with a global IPF cohort to assess cross-regional comparability and support the robustness of its trial data.
Additional posters will link buloxibutid’s observed stabilization and improvement of lung function in IPF with mechanistic findings, including changes in plasma MMP-13 and AT2 receptor activity in epithelial cells, underscoring a potential biological basis for fibrosis resolution. Vicore will also present preclinical findings in a pulmonary hypertension and fibrotic lung disease model, suggesting that AT2 receptor agonism may normalize microvasculature and reduce fibrosis, and it has been selected to present at the ATS Respiratory Innovation Summit, signaling growing recognition of its technology among industry and investment stakeholders.
The most recent analyst rating on (SE:VICO) stock is a Buy with a SEK38.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing a new class of angiotensin II type 2 receptor agonists (ATRAGs) as potentially disease-modifying treatments for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis. Its lead asset, buloxibutid, is a first-in-class oral small molecule with Orphan Drug and Fast Track designations from the U.S. FDA and is being evaluated in the global 52-week Phase 2b ASPIRE trial in IPF.
Average Trading Volume: 538,568
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.84B
Learn more about VICO stock on TipRanks’ Stock Analysis page.